MedTrace Logo

Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)

NCT03414437 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2019-03-19

No results posted yet for this study

Summary

This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastasis.

Conditions

  • Prostate Cancer Metastatic

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Carolina Research Professionals, LLC

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414437 on ClinicalTrials.gov